Business
eXoZymes Provides Fourth Quarter and Full Year 2024 Update
Management to Host Conference Call Today at 4:30PM Eastern Monrovia, CA, April 02, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential nutraceuticals, medicines, biofuels, and other valuable chemicals - provides an update on operations through the fiscal year ended December 31, 2024. Michael Heltzen, CEO of eXoZymes, states, “As a pre-revenue company, what’s important for us is that
About this update from Exozymes Inc.
[{"type":"image","alt":"eXoZymes Inc.","displaySize":"","headline":null,"caption":"eXoZymes Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/7690e51531a13747b9ca690ce6bbbb02"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jzFu1tUAndfYNerOlwv7aw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7690e51531a13747b9ca690ce6bbbb02","width":300,"height":300}},"lazy":false},{"type":"text","content":"Management to Host Conference Call Today at 4:30PM Eastern","length":58,"tagName":"p"},{"type":"text","content":"Monrovia, CA, April 02, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential nutraceuticals, medicines, biofuels, and other valuable chemicals - provides an update on operations through the fiscal year ended December 31, 2024.","length":340,"tagName":"p"},{"type":"text","content":"Michael Heltzen, CEO of eXoZymes, states, “As a pre-revenue company, what’s important for us is that we keep progressing towards our specific milestones and value infection points, like getting to our first commercial applications via spin-outs, joint-ventures, and licensing deals as the drivers of our focus on commercialization. All while making sure to keep improving our fundamental and innovative exozymes technology, as well as growing our team of talents.”","length":464,"tagName":"p"},{"type":"text","content":"Fourth Quarter and Full Year 2024 and Subsequent Operational Highlights","length":71,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Completed initial public offering: While 2024 was a challenging year to raise money for bio- and high-tech, eXoZymes successfully started trading on Nasdaq on November 13, 2024.","length":177,"tagName":"p"}]},{"val":[{"type":"text","content":"Adding AI to our biotech: Through a proprietary process, eXoZymes has developed a unique way of generating AI-derived-signal-rich enzyme data that can be used to train ML algorithms efficiently. Using this proprietary AI-based process has led to remarkable improvements in the enzyme development process, speeding up development of the core technology, and paving the way for the next generation of biomanufacturing, ...